the distinction between human and murine TB makes direct extrapolation of results

We expressed pFL84539 in mutant M7C1, to endow this mutant using the capacity for synthesizing new sugars. This plasmid encodes the bio-synthesis of Damicetose, a sugar perhaps not present in 1, and that of D olivose, CX-4945 which can be altered in the mutant strain. Analysis of the resultant strain S. argillaceus M7C1 pFL845 by HPLCMS and HPLC, unmasked the creation of many mithramycin like compounds. The major one corresponded to the previously identified demycarosylmithramycin, a compound with similar design than 1, but lacking D mycarose, the biosynthesis of which is blocked in this mutant. An additional form of mithramycin analogues was created, striving on substances with modifications in the 3 carbon side chain and the pattern. On the other hand, Plastid we've also acquired many mithramycins with antitumor activity with modifications within the glycosylation pattern, among which the most lively one was demycarosyl 3D B Ddigitoxosyl mithramycin. On the basis of this information, we set out to produce mithramycin derivatives containing both kind of structural characteristics in the chemical and expecting to improve the antitumor properties in terms of the compound. To achieve this, we provided to the S. argillaceus mutant M3W129, with the capability to synthesize N digitoxose, by expressing plasmid Oprozomib pKOL, and by expressing plasmid pMP3 BII. Plasmid pMP3 BII encodes the biosynthesis of NDP N digitoxose. Evaluation by HPLC and HPLC MS of ethyl acetate extracts of cultures of the resultant strain S. argillaceus M3W1 pMP3 BII unmasked the production of four compounds, as well as mithramycin SK and mithramycin SDK, initially produced by mutant M3W1.